Prognostic value of stem cell markers in glioblastoma

Francesc Alameda; José María Velarde; Cristina Carrato; Noemí Vidal; Montserrat Arumí; Dolores Naranjo; Maria Martinez-Garcia; Teresa Ribalta; Carme Balañá

doi:10.1080/1354750X.2019.1652345

Prognostic value of stem cell markers in glioblastoma

Francesc Alameda, José María Velarde, Cristina Carrato, Noemí Vidal, Montserrat Arumí, Dolores Naranjo, Maria Martinez-Garcia, Teresa Ribalta, Carme Balañá

Research output: Contribution to journal › Article › Research

5 Citations (Scopus)

Abstract

© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Background/Context: Glioblastoma (GB) is the most common primary brain tumour in adults and it is associated with a high mortality rate. According to the stem cell theory, the growth, relapse and treatment response of GB is determined by the stem cell subpopulation present in the tumour. Objective: Our aim is to study the prognostic value of stem cell markers (CD44, Nestin, Olig2 and SOX2) in a series of homogeneously treated GBs. Material and methods: We study 280 GBs treated with STUPP acheme with a histologican review of the cases and TMA with a máximum of 4 spots for each case. Each slide was immunohistochemically stained and Reading. We compared the immunohistochemical results with survival tme. Results: Only SOX2 immunoexpression (IE) excedding 10% of the tumour cells was found to be related to good survival (p= 0.037) in univariate analysis. However, amultivariate analysis indicate the age, surgery and MGMT promotes methylation but no SOX2 IE are prognostic factors. Conclusions: We conclude the immunohistochemical studies of stem cell markers in GB are not useful for predicting prognosis in daily practice.

Original language	English
Pages (from-to)	677-683
Journal	Biomarkers
Volume	24
DOIs	https://doi.org/10.1080/1354750X.2019.1652345
Publication status	Published - 3 Oct 2019

Keywords

CD44
Glioblastoma
Nestin
Olig2
prognosis
SOX2

Access to Document

10.1080/1354750X.2019.1652345

Cite this

@article{2ab6eff57b1f4d378e5ed3aeb009cad0,

title = "Prognostic value of stem cell markers in glioblastoma",

abstract = "{\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group. Background/Context: Glioblastoma (GB) is the most common primary brain tumour in adults and it is associated with a high mortality rate. According to the stem cell theory, the growth, relapse and treatment response of GB is determined by the stem cell subpopulation present in the tumour. Objective: Our aim is to study the prognostic value of stem cell markers (CD44, Nestin, Olig2 and SOX2) in a series of homogeneously treated GBs. Material and methods: We study 280 GBs treated with STUPP acheme with a histologican review of the cases and TMA with a m{\'a}ximum of 4 spots for each case. Each slide was immunohistochemically stained and Reading. We compared the immunohistochemical results with survival tme. Results: Only SOX2 immunoexpression (IE) excedding 10% of the tumour cells was found to be related to good survival (p= 0.037) in univariate analysis. However, amultivariate analysis indicate the age, surgery and MGMT promotes methylation but no SOX2 IE are prognostic factors. Conclusions: We conclude the immunohistochemical studies of stem cell markers in GB are not useful for predicting prognosis in daily practice.",

keywords = "CD44, Glioblastoma, Nestin, Olig2, prognosis, SOX2",

author = "Francesc Alameda and Velarde, {Jos{\'e} Mar{\'i}a} and Cristina Carrato and Noem{\'i} Vidal and Montserrat Arum{\'i} and Dolores Naranjo and Maria Martinez-Garcia and Teresa Ribalta and Carme Bala{\~n}{\'a}",

year = "2019",

month = oct,

day = "3",

doi = "10.1080/1354750X.2019.1652345",

language = "English",

volume = "24",

pages = "677--683",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Prognostic value of stem cell markers in glioblastoma

AU - Alameda, Francesc

AU - Velarde, José María

AU - Carrato, Cristina

AU - Vidal, Noemí

AU - Arumí, Montserrat

AU - Naranjo, Dolores

AU - Martinez-Garcia, Maria

AU - Ribalta, Teresa

AU - Balañá, Carme

PY - 2019/10/3

Y1 - 2019/10/3

N2 - © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Background/Context: Glioblastoma (GB) is the most common primary brain tumour in adults and it is associated with a high mortality rate. According to the stem cell theory, the growth, relapse and treatment response of GB is determined by the stem cell subpopulation present in the tumour. Objective: Our aim is to study the prognostic value of stem cell markers (CD44, Nestin, Olig2 and SOX2) in a series of homogeneously treated GBs. Material and methods: We study 280 GBs treated with STUPP acheme with a histologican review of the cases and TMA with a máximum of 4 spots for each case. Each slide was immunohistochemically stained and Reading. We compared the immunohistochemical results with survival tme. Results: Only SOX2 immunoexpression (IE) excedding 10% of the tumour cells was found to be related to good survival (p= 0.037) in univariate analysis. However, amultivariate analysis indicate the age, surgery and MGMT promotes methylation but no SOX2 IE are prognostic factors. Conclusions: We conclude the immunohistochemical studies of stem cell markers in GB are not useful for predicting prognosis in daily practice.

AB - © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Background/Context: Glioblastoma (GB) is the most common primary brain tumour in adults and it is associated with a high mortality rate. According to the stem cell theory, the growth, relapse and treatment response of GB is determined by the stem cell subpopulation present in the tumour. Objective: Our aim is to study the prognostic value of stem cell markers (CD44, Nestin, Olig2 and SOX2) in a series of homogeneously treated GBs. Material and methods: We study 280 GBs treated with STUPP acheme with a histologican review of the cases and TMA with a máximum of 4 spots for each case. Each slide was immunohistochemically stained and Reading. We compared the immunohistochemical results with survival tme. Results: Only SOX2 immunoexpression (IE) excedding 10% of the tumour cells was found to be related to good survival (p= 0.037) in univariate analysis. However, amultivariate analysis indicate the age, surgery and MGMT promotes methylation but no SOX2 IE are prognostic factors. Conclusions: We conclude the immunohistochemical studies of stem cell markers in GB are not useful for predicting prognosis in daily practice.

KW - CD44

KW - Glioblastoma

KW - Nestin

KW - Olig2

KW - prognosis

KW - SOX2

U2 - 10.1080/1354750X.2019.1652345

DO - 10.1080/1354750X.2019.1652345

M3 - Article

C2 - 31496301

SN - 1354-750X

VL - 24

SP - 677

EP - 683

JO - Biomarkers

JF - Biomarkers

ER -

Prognostic value of stem cell markers in glioblastoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this